The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Edmond J. Safra Movement Disorders Research Career Development Award, 2024Towards a Better Understanding of Treatment-refractory Gait Issues in Parkinson’s Disease
Study Rationale: Freezing of gait (FOG) is a sudden arrest of gait despite the intention to continue walking, often while a person is turning, walking in a confined space or is in a situation that...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2024Preclinical Testing of Novel DBS Protocol for Long-Lasting Therapeutic Effects
Study Rationale: Deep brain stimulation is an effective therapy for motor symptoms of late-stage Parkinson’s disease. It works like a pacemaker to interrupt abnormal patterns of brain activity that...
-
Therapeutic Pipeline Program, 2024Photoreceptor-directed Light Therapy in Parkinson’s Disease
Study Rationale: Non-motor symptoms including sleep disturbances are common and enormously impact on the quality of life in people with Parkinson’s disease. Sleep disruption affects motor function and...
-
Freezing of Gait, 2024Adaptive Cortical Neuromodulation Using a Brain-machine Interface to Treat Freezing of Gait in Parkinson’s Disease
Study Rationale: Difficulties with walking can have significant impacts on the quality of life of people with Parkinson’s (PwP). One of the most serious is freezing of gait (FOG), which are brief but...
-
Freezing of Gait, 2024TURN-IT: A Novel Intervention to Improve Turning in People with PD and Freezing of Gait
Study Rationale: Turning is a critical aspect of mobility for people with PD that, in some individuals, can precipitate freezing of gait. We recently developed a turn-specific intervention for people...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Novel LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Study Rationale: Inhibitors of the LRRK2 protein offer promise as a therapy for Parkinson’s disease (PD). The leading inhibitors currently under development, the so-called Type 1 kinase inhibitors...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.